{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,20]],"date-time":"2026-09-20T05:59:04Z","timestamp":1789883944277,"version":"4.0.1"},"reference-count":10,"publisher":"Wiley","issue":"4","license":[{"start":{"date-parts":[[2004,8,9]],"date-time":"2004-08-09T00:00:00Z","timestamp":1092009600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Int J Dermatology"],"published-print":{"date-parts":[[2005,4]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p><jats:bold>Background\u2002<\/jats:bold> Topical psoralen plus UVA (PUVA) is an effective treatment for localized forms of eczema, psoriasis, and palmoplantar pustulosis, which avoids some of the undesirable side\u2010effects of systemic psoralens.<\/jats:p><jats:p><jats:bold>Aims\u2002<\/jats:bold> In this study, the efficacy of topical PUVA treatment with 8\u2010methoxypsoralen (8\u2010MOP) gel was compared with placebo plus UVA in chronic recurrent palmoplantar dermatoses.<\/jats:p><jats:p><jats:bold>Methods\u2002<\/jats:bold> Twenty\u2010two patients with palmoplantar disease (11 with psoriasis vulgaris, six with eczema, and five with pustulosis) were enrolled in the study. The study design was a left\u2013right comparison: one hand or foot was treated with 8\u2010MOP 0.01% gel plus UVA, whilst the contralateral hand or foot received placebo and UVA for 6\u00a0weeks. Twenty minutes after application of the gel, both sides were exposed to UVA. The treatment regimen was three times a week, and the UVA dose was increased weekly by 20%.<\/jats:p><jats:p><jats:bold>Results\u2002<\/jats:bold> A comparison of the pre\u2010 and post\u2010treatment scores with regard to the severity of the clinical picture and the infiltration of plaques showed a significant decrease (from 7.5\u00a0\u00b1\u00a02.0 to 2.5\u00a0\u00b1\u00a02.1 and from 2.0\u00a0\u00b1\u00a00.7 to 0.3\u00a0\u00b1\u00a00.5, respectively) in the sites treated with 8\u2010MOP gel compared with placebo after 6\u00a0weeks.<\/jats:p><jats:p><jats:bold>Conclusion\u2002<\/jats:bold> The results of the study indicate that at least 18 courses of local PUVA within 6\u00a0weeks, with a cumulative dose of 87\u00a0J\/cm<jats:sup>2<\/jats:sup>, are required to induce a significant decrease in the disease severity and an improvement in the infiltration of plaques due to 8\u2010MOP gel at a concentration of 0.01% when treating chronic recurrent palmoplantar dermatoses.<\/jats:p>","DOI":"10.1111\/j.1365-4632.2004.02153.x","type":"journal-article","created":{"date-parts":[[2005,3,30]],"date-time":"2005-03-30T14:21:03Z","timestamp":1112192463000},"page":"337-339","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":27,"title":["Evaluation of time\u2010dependent response to psoralen plus UVA (PUVA) treatment with topical 8\u2010methoxypsoralen (8\u2010MOP) gel in palmoplantar dermatoses"],"prefix":"10.1111","volume":"44","author":[{"given":"Burhan","family":"Engin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oya","family":"Oguz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2005,1,21]]},"reference":[{"key":"e_1_2_5_2_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2133.2000.03237.x"},{"key":"e_1_2_5_3_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2230.1994.tb01251.x"},{"key":"e_1_2_5_4_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2133.1980.tb06565.x"},{"key":"e_1_2_5_5_2","doi-asserted-by":"crossref","first-page":"354","DOI":"10.2340\/0001555561354356","article-title":"Inefficacy of topical methoxalen plus UVA for palmoplantar pustulosis","volume":"61","author":"Jansen CT","year":"1981","journal-title":"Acta Derm Venereol"},{"key":"e_1_2_5_6_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0025-6196(11)63721-X"},{"key":"e_1_2_5_7_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2133.1999.02898.x"},{"key":"e_1_2_5_8_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199704103361501"},{"key":"e_1_2_5_9_2","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(19940601)73:11<2759::AID-CNCR2820731118>3.0.CO;2-C"},{"key":"e_1_2_5_10_2","first-page":"495","volume-title":"Dermatology in General Medicine","author":"Christophers E","year":"1999"},{"key":"e_1_2_5_11_2","doi-asserted-by":"publisher","DOI":"10.1067\/mjd.2001.112360"}],"container-title":["International Journal of Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1365-4632.2004.02153.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1365-4632.2004.02153.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,10]],"date-time":"2023-10-10T06:42:07Z","timestamp":1696920127000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1365-4632.2004.02153.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005,1,21]]},"references-count":10,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2005,4]]}},"alternative-id":["10.1111\/j.1365-4632.2004.02153.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1365-4632.2004.02153.x","archive":["Portico"],"relation":{},"ISSN":["0011-9059","1365-4632"],"issn-type":[{"value":"0011-9059","type":"print"},{"value":"1365-4632","type":"electronic"}],"subject":[],"published":{"date-parts":[[2005,1,21]]},"assertion":[{"value":"2005-01-21","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}